Share on StockTwits

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its quarterly earnings data on Monday. The company reported $2.61 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.94, StockRatingsNetwork reports. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million.

A number of analysts have recently weighed in on ENTA shares. Analysts at JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Analysts at Robert W. Baird downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, June 24th. They now have a $41.00 price target on the stock. They noted that the move was a valuation call.

Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 38.40 on Monday. Enanta Pharmaceuticals has a one year low of $18.00 and a one year high of $46.443. The stock’s 50-day moving average is $40.27 and its 200-day moving average is $38.13. The company’s market cap is $711.8 million.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.